Question 1

What is Sumitomo Pharma?

Accepted Answer

Sumitomo Pharma is a Company.

Question 2

How often does Sumitomo Pharma appear in global news?

Accepted Answer

Tracked across 5 news events drawn from 112 articles.

Question 3

When was Sumitomo Pharma first tracked by Ergen?

Accepted Answer

First tracked on Mar 06, 2026.

Question 4

When was Sumitomo Pharma last mentioned in news?

Accepted Answer

Last active on Aug 19, 2026.

Question 5

What is Sumitomo Pharma's current news sentiment?

Accepted Answer

Aggregate sentiment score: -2 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Sumitomo Pharma in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 5 events.

Question 7

What is the most recent event involving Sumitomo Pharma?

Accepted Answer

Japan Approves Stem-Cell Therapies (Mar 06, 2026, 6 articles).

Question 8

How did the "Japan Approves Stem-Cell Therapies" event impact Sumitomo Pharma?

Accepted Answer

Sumitomo Pharma received conditional and time-limited approval for its Parkinson's disease treatment, Amchepry, which is expected to be the world's first commercially available iPS cell product. This approval significantly boosts the company's market position in regenerative medicine.

Question 9

How did the "Japanese Market Declines Amid Geopolitical Tensions" event impact Sumitomo Pharma?

Accepted Answer

Sumitomo Pharma's stock slipped, indicating a negative trend for the company.

Question 10

How did the "Nikkei 225 Reaches All-Time Highs" event impact Sumitomo Pharma?

Accepted Answer

Sumitomo Pharma's stock was down, showing a negative performance.

Question 11

How did the "Japanese stocks volatile amid Middle East tensions" event impact Sumitomo Pharma?

Accepted Answer

Sumitomo Pharma was down almost 3% on one day, reflecting losses.

Question 12

How did the "Poxel Appoints Yves Decadt CEO" event impact Sumitomo Pharma?

Accepted Answer

Sumitomo Pharma>>> markets Imeglimin, a drug from Poxel>>>, in Japan for type 2 diabetes, demonstrating the drug's clinical efficacy and commercial potential.

Question 13

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.